Abstract
100% of primary human hepatocytes infected with an adenoviral vector carrying β-galactosidase expressed the exogenous gene. Expression was also achieved in > 40% of adult mouse hepatocytes in vivo. Normal levels of activity were achieved in mouse ornithine transcarbamylase (OTC)-deficient primary hepatocytes using another adenoviral vector carrying human OTC cDNA. Study of OTC-deficient primary human hepatocytes from a single patient confirmed the utility of adenoviral delivery of OTC. We describe adenoviral-mediated exogenous gene expression in human and mouse hepatocytes in vitro and in mouse liver in vivo. Data suggest that adenoviral vectors may be useful for correcting OTC deficiency.
Original language | English (US) |
---|---|
Pages (from-to) | 1580-1586 |
Number of pages | 7 |
Journal | Journal of Clinical Investigation |
Volume | 92 |
Issue number | 3 |
DOIs | |
State | Published - Sep 1993 |
Keywords
- β-galactosidase
- Gene therapy
- Human
- Liver
- Ornithine transcarbamylase
ASJC Scopus subject areas
- General Medicine